Can we decrease the acute proctitis in prostate cancer patients using hyaluronic acid during radiation therapy: A prospective historically controlled clinical study

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 5, 2012, Pages 639-645

  Stefanelli, A ^a   Pascale, G ^a   Rainieri, E ^a   Ursino, S ^a   Colella, M ^a   Zini, G ^a   Berretta, M ^b   Fiorica, Francesco ^a  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Acute proctitis; Hyaluronic acid; Radiotherapy prophylaxis

Indexed keywords

CICATRIDINA; HYALURONIC ACID; UNCLASSIFIED DRUG; RADIOPROTECTIVE AGENT;

ADJUVANT THERAPY; AGED; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; PROCTITIS; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION INJURY; REVIEW; SUPPOSITORY; ACUTE DISEASE; ARTICLE; CASE CONTROL STUDY; ITALY; KAPLAN MEIER METHOD; MORTALITY; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PROSTATE TUMOR; RADIOTHERAPY; RECTAL DRUG ADMINISTRATION; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, RECTAL; AGED; CASE-CONTROL STUDIES; HUMANS; HYALURONIC ACID; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; PROCTITIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTORS; SUPPOSITORIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864108293     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. GARCIA M, JEMAL A, WARD EM, CENTER MM, HAO Y, SIEGEL RL, THUN MJ. Global Cancer Facts & Figures, American Cancer Society, Atlanta, GA. http://www.cancer.org/downloads/STT/Global-Ca ncer-Facts-and-Figures-20070rev. pdf; 2007.
2. KUBAN DA, TUCKER SL, DONG L, STARKSCHALL G, HUANG EH, CHEUNG MR, LEE AK, POLLACK A. LONGTERM RESULTS OF THE M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 67-74.
3. ZELEFSKY MJ, YAMADA Y, FUKS Z, ZHANG Z, HUNT M, CAHLON O, PARK J, SHIRPY A. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation in biochemical tumor control and distant metastates-free survival outcomes. Int J Radiat Oncol Biol Phys 2008; 71: 1028-1033.
4. DEARNALEY DP, SYDES MR, GRAHAM JD, AIRD EG, BOTTOMLEY D, COWAN RA, HUDDART RA, JOSE CC, MATTHEWS JH, MILLAR J, MOORE AR, MORGAN RC, RUSSELL JM, SCRASE CD, STEPHENS RJ, SYNDIKUS I, PARMAR MK; RT01 COLLABORATORS. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475-487.
5. GRECO C, MAZZETTA C, CATTANI F, TOSI G, CASTIGLIONI S, FODOR A, ORECCHIA R. Finding dose-volume constraints to reduce late rectal toxicity following 3Dconformal radiotherapy (3D-CRT) of prostate cancer. Radiother Oncol 2003; 69: 215-222.
6. MARTENSON JA, BOLLINGER JW, SLOAN JA, NOVOTNY PJ, URIAS RE, MICHALAK JC, SHANAHAN TG, MAILLIARD JA, LEVITT R. Sucralfate in the prevention of treatment- induced diarrhea in patients receiving pelvic radiation therapy: A North Central cancer Treatment Group phase III double-blind placebo-controlled trial. J Clin Oncol 2000; 18: 1239-1245.
7. KNEEBONE A, MAMEGHAN H, BOLIN T, BERRY M, TURNER S, KEARSLEY J, GRAHAM P, FISHER R. The effect of oral sucralfate on the acute proctitis associated with prostate radiotherapy: A double-blind, randomized trial. Int J Radiat Oncol Biol Phys 2001; 51: 628-635.
8. SANGUINETTI G, FRANZONE P, MARCENARO M, FOPPIANO F, VITALE V. Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study. Strahlenther Onkol 2003; 179: 464-470.
9. HOVDENAK N, SORBYE H, DAHL O. Sucralfate does not ameliorate acute radiation proctitis: Randomised study and meta-analysis. Clin Oncol (R Coll Radiol) 2005; 17: 485-491.
10. KILIC D, OZENIRLER S, EGEHAN I, DURSUN A. Sulfasalazine decreases acute gastrointestinal complications due to pelvic radiotherapy. Ann Pharmacother 2001; 35: 806-810.
11. SEO EH, KIM TO, KIM TG, JOO HR, PARK J, PARK SH, YANG SY, MOON YS, PARK MJ, RYU DY, SONG GA. The efficacy of the combination therapy with oral and topical mesalazine for patients with the first episode of radiation proctitis. Dig Dis Sci 2011; 56: 2672-2677.
12. POBICO P, CAPIRCI C, STEVANIN C, MANDOLITI C, LAVEDER F, RIMONDI AP. Acute rectal injury during pelvic RT: Clinic-histological study and its prevention by 5-aminosalicylic acid. Radiother Oncol 1994; 32: S41.
13. JAHRAUS CD, BETTENHAUSEN D, MALIK U, SELLITTI M, ST CLAIR WH. Prevention of acute radiation-induced proctosigmoiditis by balsalazide: A randomized, double-blind, placebo controlled trial in prostate cancer patients. Int J Radiat Oncol Biol Phys 2005; 63: 1483-1487.
14. FUCCIO L, GUIDO A, LATERZA L, EUSEBI LH, BUSUTTI L, BUNKHEILA F, BARBIERI E, BAZZOLI F. Randomised clinical trial: Preventive treatment with topical rectal beclomethasone dipropionate reduces post-radiation risk of bleeding in patients irradiated for prostate cancer. Aliment Pharmacol Ther 2011; 34: 628-637.
15. SHAO Y, LU GL, SHEN ZJ. Comparison of intravesical hyaluronic acid instillation and hyperbaric oxygen in the treatment of radiation-induced hemorrhagic cystitis. BJU Int 2011. doi: 10.1111/j.1464- 410X.2011.10550.x. [Epub ahead of print]
16. PINNIX C, PERKINS GH, STROM EA, TEREFFE W, WOODWARD W, OH JL, ARRIAGA L, MUNSELL MF, KELLY P, HOFFMAN KE, SMITH BD, BUCHHOLZ TA, YU TK. Topical hyaluronic acid vs. standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer: Single-blind randomized phase III clinical trial. Int J Radiat Oncol Biol Phys. 2011 Dec 14. [Epub ahead of print]
17. RIEHL TE, FOSTER L, STENSON WF. Hyaluronic Acid is Radioprotective in the intestine through a TLR-4 and COX-2 mediated mechanism. Am J Physiol Gastrointest Liver Physiol 2011 Oct 28.
18. COX JD, STETZ J, PAJAK TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
19. PICCIRILLO JF, TIERNEY RM, COSTAS I, GROVE L, SPITZNAGEL EL JR. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441-2447.
20. KOPER PC, STROOM JC, VAN PUTTEN WL, KOREVAAR GA, HEIJMEN BJ, WIJNMAALEN A, JANSEN PP, HANSSENS PE, GRIEP C, KROL AD, SAMSON MJ, LEVENDAG PC. Acute morbidity reduction using 3DCRT for prostate carcinoma: A randomized study. Int J Radiat Oncol Biol Phys 1999; 43: 727-734.
21. MICHALSKI JM, BAE K, ROACH M, MARKOE AM, SANDLER HM, RYU J, PARLIAMENT MB, STRAUBE W, VALICENTI RK, COX JD. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys 2010; 76: 14-22.
22. STOREY MR, POLLACK A, ZAGARS G, SMITH L, ANTOLAK J, ROSEN I. Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000; 48: 635-642.
23. WITHERS HR, MASON KA. The kinetics of recovery in irradiated colonic mucosa of the mouse. Cancer 1974; 34(suppl): 896-903.
24. HOVDENAK N, FAJARD LF, HAUER-JENSEN M. Acute radiation proctitis: A sequential clinicopathologic study during pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48: 1111-1117.
25. SATO H, TAKAHASHI T, IDE H, FUKUSHIMA T, TABATA M, SEKINE F, KOBAYASHI K, NEGISHI M, NIWA Y. Antioxidant activity of synovial fluid, hyaluronic acid, and two subcomponents of hyaluronic acid. Synovial fluid scavenging effect is enhanced in rheumatoid arthritis patients. Arthritis Rheum 1988; 31: 63-71.
26. KUMAR S, JURESIC E, BARTON M, SHAFIQ J. Management of skin toxicity during radiation therapy: A review of the evidence. J Med Imaging Radiat Oncol 2010; 54: 264-279.
27. GILL S, THOMAS J, FOX C, KRON T, ROLFO A, LEAHY M, CHANDER S, WILLIAMS S, TAI KH, DUCHESNE GM, FOROUDI F. Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiat Oncol 2011; 6: 145.
28. VAN HAAREN PM, BEL A, HOFMAN P, VAN VULPEN M, KOTTE AN, VAN DER HEIDE UA. Influence of daily setup measurements and corrections on the estimated delivered dose during IMRT treatment of prostate cancer patients. Radiother Oncol 2009; 90: 291-298.